rNAPc2: Phase IIa data

In the double-blind, dose-escalation, U.S. and Canadian Phase IIa ANTHEM/TIMI 32 trial in 203 patients, rNAPc2 inhibited thrombin generation without increasing bleeding. Major and minor bleed rate wit...